With imatinib, long-term survival of adult patients with Ph+ ALL was substantially improved in trial UKALLXII/ECOG299, to a greater extent in patients receiving the drug since induction phase II (early) rather than consolidation therapy (late). See Figure 2B in the article by Fielding et al that begins on page 843.